La Trobe

Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop

journal contribution
posted on 2025-01-09, 02:25 authored by Jackie L Whittaker, Raneem Kalsoum, James Bilzon, Philip G Conaghan, Kay CrossleyKay Crossley, George R Dodge, Alan Getgood, Xiaojuan Li, Elena Losina, Deborah J Mason, Brian Pietrosimone, May Arna Risberg, Frank Roemer, David Felson, Adam CulvenorAdam Culvenor, Duncan Meuffels, Nicole Gerwin, Lee S Simon, L Stefan Lohmander, Martin Englund, Fiona E Watt

Objective: The global impact of osteoarthritis is growing. Currently no disease modifying osteoarthritis drugs/therapies exist, increasing the need for preventative strategies. Knee injuries have a high prevalence, distinct onset, and strong independent association with post-traumatic osteoarthritis (PTOA). Numerous groups are embarking upon research that will culminate in clinical trials to assess the effect of interventions to prevent knee PTOA despite challenges and lack of consensus about trial design in this population. Our objectives were to improve awareness of knee PTOA prevention trial design and discuss state-of-the art methods to address the unique opportunities and challenges of these studies.

Design: An international interdisciplinary group developed a workshop, hosted at the 2023 Osteoarthritis Research Society International Congress. Here we summarize the workshop content and outputs, with the goal of moving the field of PTOA prevention trial design forward.

Results: Workshop highlights included discussions about target population (considering risk, homogeneity, and possibility of modifying osteoarthritis outcome); target treatment (considering delivery, timing, feasibility and effectiveness); comparators (usual care, placebo), and primary symptomatic outcomes considering surrogates and the importance of knee function and symptoms other than pain to this population.

Conclusions: Opportunities to test multimodal PTOA prevention interventions across preclinical models and clinical trials exist. As improving symptomatic outcomes aligns with patient and regulator priorities, co-primary symptomatic (single or aggregate/multidimensional outcome considering function and symptoms beyond pain) and structural/physiological outcomes may be appropriate for these trials. To ensure PTOA prevention trials are relevant and acceptable to all stakeholders, future research should address critical knowledge gaps and challenges.

Funding

FW is a recipient of a fellowship from UK Research & Innovation, a UK government supported research which includes the Medical Research Council (MR/S016538/1, MR/S016538/2 and MR/Y003470/1) . This fellowship directly supported FW and RK in their time in coordinating all aspects of this work and in the writing of the manuscript. JW is supported by an Arthritis Society (Canada) STARS career development award (STAR 19 - 0493) and Michael Smith Health Research BC Scholar award (SCH-2020-0403) . AC is a recipient of a National Health and Medical Research Council (NHMRC) of Australia Investigator Grant (GNT2008523) . PC is supported in part by the United Kingdom National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis (funded by Versus Arthritis, 21595) covered limited speaker travel costs associated with the workshop. Funding sources had no role in the review or contents of this manuscript.

History

Publication Date

2024-06-01

Journal

Osteoarthritis and Cartilage Open

Volume

6

Issue

2

Article Number

100449

Pagination

11p.

Publisher

Elsevier

ISSN

2665-9131

Rights Statement

© 2024 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International (OARSI). This is an open access article under the Creative Commons Attribution (CC BY) license: https://creativecommons.org/licenses/by/4.0

Usage metrics

    Journal Articles

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC